Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street ZenMarket Beat·Aug 15 at 12:42 AMELDN-2.56%
ELDN: Tegoprubart shows superior efficacy and safety over tacrolimus in transplant trialsQuartr·Aug 13 at 03:43 PMELDN-2.56%
NewcelX prices USD 1.4 million private placement at USD 4.03 per sharePUBT·Jul 31 at 08:00 AMNCEL-4.97%ELDN-2.56%
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga_article·Jul 21 at 06:58 AMTRVI-6.12%ELDN-2.56%
NewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036PUBT·Jul 15 at 08:03 AMNCEL-4.97%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·Jul 10 at 04:05 PMOKYO+2.06%UPC-8.93%
NewcelX appoints diabetes researcher Camillo Ricordi to scientific advisory boardPUBT·Jul 8 at 08:15 AMNCEL-4.97%ELDN-2.56%
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | NCEL Stock NewsStockTitan·Jul 8 at 12:15 AMNCEL-4.97%ELDN-2.56%
NewcelX reports successful FDA pre-IND meeting for NCEL-101 type 1 diabetes trial planPUBT·Jul 2 at 01:32 PMNCEL-4.97%ELDN-2.56%
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | NCEL Stock NewsStockTitan·Jul 1 at 12:30 AMNCEL-4.97%ELDN-2.56%
Natera partners with Eledon to supply Prospera monitoring for planned Phase 3 kidney transplant trialPUBT·Jun 25 at 06:00 AMNTRA-3.54%ELDN-2.56%
